Plerixafor Plus Granulocyte Colony-Stimulating Factor Improves the Mobilization of Hematopoietic Stem Cells in Patients with Non-Hodgkin Lymphoma and Low Circulating Peripheral Blood CD34+ Cells

Biology of Blood and Marrow Transplantation

Volumn 19, Issue 4, 2013, Pages 670-675

  Maziarz, Richard T ^a   Nademanee, Auayporn P ^b   Micallef, Ivana N ^c   Stiff, Patrick J ^d   Calandra, Gary ^e   Angell, Jennifer ^e   DiPersio, John F ^f   Bolwell, Brian J ^g  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^c MAYO CLINIC   (United States)

^d LOYOLA UNIVERSITY CHICAGO   (United States)

^e GENZYME CORPORATION   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Non Hodgkin lymphoma; Peripheral blood stem cell mobilization; Plerixafor

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; PLACEBO; PLERIXAFOR;

ADULT; AGED; APHERESIS; ARTICLE; CANCER PATIENT; CELL COUNT; CONTROLLED STUDY; HEMATOPOIETIC STEM CELL; HUMAN; MAJOR CLINICAL STUDY; MORNING DOSAGE; NONHODGKIN LYMPHOMA; POST HOC ANALYSIS; RETROSPECTIVE STUDY; STEM CELL MOBILIZATION;

ADULT; AGED; ANTIGENS, CD34; BLOOD COMPONENT REMOVAL; CD4 LYMPHOCYTE COUNT; DOUBLE-BLIND METHOD; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; LEUKOCYTES, MONONUCLEAR; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; PLACEBOS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84875510663     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2013.01.005     Document Type: Article

References (25)

1. NCCN Clinical Practice Guidelines in Oncology. Non-Hodgkin's Lymphoma v.1.2010. Available at:. Accessed January 2010. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#hodgkin.
2. Pavone V., Gaudio F., Console G., et al. Poor mobilization is an independent prognostic factor in patients with malignant lymphomas treated by peripheral blood stem cell transplantation. Bone Marrow Transplant 2006, 37:719-724.
3. Pusic I., Jiang S.Y., Landua S., et al. Impact of mobilization and remobilization strategies on achieving sufficient stem cell yields for autologous transplantation. Biol Blood Marrow Transplant 2008, 14:1045-1056.
4. Bensinger W., DiPersio J.F., McCarty J.M. Improving stem cell mobilization strategies: future directions. Bone Marrow Transplant 2009, 43:181-195.
5. Fowler C.J., Dunn A., Hayes-Lattin B., et al. Rescue from failed growth factor and/or chemotherapy HSC mobilization with G-CSF and plerixafor (AMD3100): an institutional experience. Bone Marrow Transplant 2009, 43:909-917.
6. Basquiera A.L., Abichain P., Damonte J.C., et al. The number of CD34(+) cells in peripheral blood as a predictor of the CD34(+) yield in patients going to autologous stem cell transplantation. J Clin Apher 2006, 21:92-95.
7. Demirer T., Buckner C.D., Bensinger W.I. Optimization of peripheral blood stem cell mobilization. Stem Cells 1996, 14:106-116.
8. Fontão-Wendel R., Lazar A., Melges S., et al. The absolute number of circulating CD34+ cells as the best predictor of peripheral hematopoietic stem cell yield. J Hematother 1999, 8:255-262.
9. Mozobil [package insert] 2010, Genzyme Corporation, Cambridge, MA.
10. Dipersio J.F., Micallef I.N., Stiff P.J., et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granulocyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009, 27:4767-4773.
11. DiPersio J.F., Stadtmauer E.A., Nademanee A., et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009, 113:5720-5726.
12. Hatse S., Princen K., Bridger G., et al. Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett 2002, 527:255-262.
13. Liles W.C., Rodger E., Broxmeyer H.E., et al. Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonist. Transfusion 2005, 45:295-300.
14. Broxmeyer H.E., Orschell C.M., Clapp D.W., et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005, 201:1307-1318.
15. Calandra G., McCarty J., McGuirk J., et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008, 41:331-338.
16. Duarte R.F., Shaw B.E., Marín P., et al. Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data. Bone Marrow Transplant 2010, 46:52-58.
17. D'Addio A., Curti A., Worel N., et al. The addition of plerixafor is safe and allows adequate PBSC collection in multiple myeloma and lymphoma patients poor mobilizers after chemotherapy and G-CSF. Bone Marrow Transplant 2010, 46:356-363.
18. Hubel K., Fresen M.M., Salwender H., et al. Plerixafor with and without chemotherapy in poor mobilizers: results from the German compassionate use program. Bone Marrow Transplant 2011, 46:1045-1052.
19. Dugan M.J., Maziarz R.T., Bensinger W.I., et al. Safety and preliminary efficacy of plerixafor (Mozobil) in combination with chemotherapy and G-CSF: an open-label, multicenter, exploratory trial in patients with multiple myeloma and non-Hodgkin's lymphoma undergoing stem cell mobilization. Bone Marrow Transplant 2010, 45:39-46.
20. Giralt S., Stadtmauer E.A., Harousseau J.L., et al. International Myeloma Working Group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia 2009, 23:1904-1912.
21. Bolwell B.J., Auayporn P., Nademanee A., et al. Mobilization with plerixafor (Mobozil®) plus G-CSF results in superior day 1 collection of CD34+ cells compared to placebo plus G-CSF: Results from two randomized placebo-controlled trials in patients with multiple myeloma or Non-Hodgkin's Lymphoma. Blood 2009, 114:3224.
22. Wuchter P., Ran D., Bruckner T., et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010, 16:490-499.
23. Demirer T., Ilhan O., Ayli M., et al. Monitoring of peripheral blood CD34+ cell counts on the first day of apheresis is highly predictive for efficient CD34+ cell yield. Ther Apher 2002, 6:384-389.
24. Gee A.P., Lamb L.S. Enumeration of CD34-positive hematopoietic progenitor cells. Immunophenotyping 2000, 291. Wiley-Liss, New York, NY. 1st ed. C.C. Stewart, J.K.A. Nicholson (Eds.).
25. Van Craenenbroeck E.M., Conraads V.M., Van Bockstaele D.R., et al. Quantification of circulating endothelial progenitor cells: a methodological comparison of six flow cytometric approaches. J Immunol Methods 2008, 332:31-40.